Get the Stockscreener App
28.78
2.47%
-0.73
After Hours:
28.72
-0.06
-0.21%
ARK Genomic Revolution ETF stock is traded at $28.78, with a volume of 2.20M.
It is down -2.47% in the last 24 hours and up +4.69% over the past month.
The investment seeks long-term growth of capital.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
See More
Previous Close:
$29.51
Open:
$29.07
24h Volume:
2.20M
Relative Volume:
0.80
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.82%
1M Performance:
+4.69%
6M Performance:
+12.77%
1Y Performance:
+20.02%
1-Day Range:
$28.44
$29.50
1-Week Range:
$28.03
$30.28
52-Week Range:
$17.50
$34.39
ARK Genomic Revolution ETF Stock (ARKG) Company Profile
Name
ARK Genomic Revolution ETF
Sector
Industry
Phone
855-406-1506
Address
-
Compare ARKG vs VTI, SPY, IVV, VB, QQQ
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARKG
ARK Genomic Revolution ETF
|
28.78 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
336.00 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
State Street Spdr S P 500 Etf Trust
|
681.31 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
684.46 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
271.12 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
608.91 | 124.43B | 0 | 0 | 0 | 0.00 |
ARK Genomic Revolution ETF Stock (ARKG) Latest News
ARK Funds Investment Guide: ETFs, Strategy & How to Buy in 2026 - Bitget
ARK Invest Strategy: Thematic ETFs & Disruptive Innovation Investing Guide - Bitget
Top ARK Invest Funds 2026: ARKK, ARKG, ARKF & ARKQ Analysis Guide - Bitget
How to Track Cathie Wood's ARK Invest Portfolio & Trading Strategies 2026 - Bitget
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing - The Motley Fool
Cathie Wood's weekly recap: adds defense stock Kratos, CoreWeave, Baidu (ARKK:BATS) - Seeking Alpha
Cathie Wood's ARK Invest weekly recap: parks in crypto, AI healthcare; offloads ABNB, PD, PINS - MSN
Cathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 MillionTempus AI (NASDAQ:TEM) - Benzinga
Cathie Wood's weekly recap: adds AMD, CRSP; cuts PINS, PD, TER (ARKK:BATS) - Seeking Alpha
Cathie Wood adds 210K shares to a rising AI bet with upside of 102% - MSN
Why Tempus AI Stock Is Plunging This Week - AOL.com
Friday's ETF Movers: GTOP, ARKG - Nasdaq
Cathie Wood Scoops Up $24M in Figma, Sells DraftKings - TipRanks
What's Going On With Tempus AI Stock Today? - Benzinga
Five years later, Cathie Wood's ARKK is still down over 50% since its 2021 peak - Seeking Alpha
Cathie Wood Adds 210K Shares to a Rising AI Bet With Upside of 102% - Yahoo Finance
(ARKG) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio - TipRanks
Top ETFs Tracking CRISPR Gene Editing for 2026 - The Motley Fool
Tracking Cathie Wood’s ARK Invest 13F Portfolio – Q4 2025 Update (BATS:ARKK) - Seeking Alpha
7 Best Biotech ETFs to Buy Now | Investing | U.S. News - US News Money
Why Is Personalis Stock Soaring Tuesday?Personalis (NASDAQ:PSNL) - Benzinga
Cathie Wood Ark Invest bets bigger on Bullish amid 16% surge - Cryptopolitan
Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test - Sahm
(ARKG) Risk Channels and Responsive Allocation - Stock Traders Daily
Best Biotech ETFs to Buy in 2026 - The Motley Fool
Best Genetic Sequencing Stocks to Buy in 2026 and How to Invest in Them - The Motley Fool
What's Going On With Tempus AI Stock Monday? - Benzinga
Cathie Wood wraps up 2025 with new biotech buys — here’s what it sold - MSN
ARKG: Cathie Wood's Biotech Product Is In Rally Mode (BATS:ARKG) - Seeking Alpha
Cathie Wood's weekly recap: buys WeRide, crypto names, trims defense firm Kratos, PINS, META (ARKK:BATS) - Seeking Alpha
Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops - Benzinga
Cathie Wood Sells Biotech Stocks, Bets Big on Tempus AI and WeRide - TipRanks
Cathie Wood Bets Big On AI Trifecta: Ark Deploys $1.4 Million Across Medical, Autonomous Driving Sectors - Benzinga
Ark Invest Increases Stakes in Multiple AI Firms - intellectia.ai
(ARKG) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ARK Invest seeks approval for CoinDesk 20 crypto index ETFs - MSN
Friday's ETF Movers: SLVR, ARKG - Nasdaq
Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI - Blockonomi
ETFs with a political spin: An investable theme or an asset-gathering play? - Pensions & Investments
Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI - CoinCentral
Cathie Wood Dumps Over $5M in a Biotech Stock, Buys WeRide and Tempus AI - TipRanks
Ark Invest Boosts Tempus AI Holdings with $925K Purchase Amid 83% Revenue Surge - Intellectia AI
Cathie Wood Loads Up On This Robotaxi Stock, Ark Dumps Roku In Latest Trades - Benzinga
How to Invest in the New Era of Agentic AI for Biotech Stocks - FinancialContent
Cathie Wood Buys Netflix and AI Stocks, Dumps Beam, PINS, and GitLab Shares - TipRanks
Cathie Wood buys the Netflix dip as shares slide on WBD deal jitters - MSN
ARK Genomic Revolution ETF Stock (ARKG) Financials Data
There is no financial data for ARK Genomic Revolution ETF (ARKG). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.30%
0.06%
Cap:
|
Volume (24h):